日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer

放射影像检查后的护理是否已经过时?ctDNA检测呈阳性如何预示着低风险激素受体阳性乳腺癌患者晚期复发?

Pfister, Kerstin; Huesmann, Sophia; Fink, Angelina; Friedl, Thomas W P; Mergel, Franziska; Schäffler, Henning P; Hartkopf, Andreas; Lukac, Stefan; Veselinovic, Kristina; Mehmeti, Forca; Campbell, Nathan; Pipinikas, Christodoulos; Deininger, Katharina; Beer, Ambros; Lorenz, Stefanie; Beer, Meinrad; Wiesmüller, Lisa; Janni, Wolfgang; Heublein, Sabine; Rack, Brigitte

The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors

SURVIVE 研究 (NCT05658172):将乳腺癌术后护理带入 21 世纪:一项 III 期临床试验的研究方案,比较液体活检指导与标准护理监测对中高危乳腺癌幸存者的影响

Braun, Tatjana; Huesmann, Sophia; Pfister, Kerstin; Friedl, Thomas W P; Hartkopf, Andreas; Pantel, Klaus; Mehmeti, Forca; Mergel, Franziska; Schäffler, Henning; Heublein, Sabine; Wiesmüller, Lisa; Rack, Brigitte; Fasching, Peter A; Janni, Wolfgang; Fink, Angelina

Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy

SURVIVE HERoes 研究方案 (NCT06643585):曲妥珠单抗德鲁替康用于 HER2+/低危早期乳腺癌患者在接受初始治疗后出现分子复发,且 ctDNA 阳性

Pfister, Kerstin; Friedl, Thomas W P; Hartkopf, Andreas; Mergel, Franziska; Huesmann, Sophia; Mehmeti, Forca; Schäffler, Henning; Fink, Angelina; Braun, Tatjana; Heublein, Sabine; Wiesmüller, Lisa; Pantel, Klaus; Rack, Brigitte; Fasching, Peter A; Janni, Wolfgang